CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), PDGFRα inhibitors(Platelet-derived growth factor receptor alpha inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [4]

Active Indication

Malignant Gastric Gastrointestinal Stromal TumorIslet Cell CarcinomaIslet Cell Adenoma+ [13]

Inactive Indication

Adenocarcinoma of prostateAdrenocortical CarcinomaAdvanced breast cancer+ [95]

Originator Organization

Pfizer Inc.

Active Organization

MSD KK (Tokyo)Pfizer Ltd.Accord Healthcare SL

+ [5]

Inactive Organization

HK inno.N Corp.

Novartis Pharmaceuticals Corp.Huizhi Pharmaceutical (Dalian) Co., Ltd.

+ [6]

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (26 Jan 2006),

Advanced Renal Cell CarcinomaGastrointestinal Stromal Tumors

RegulationAccelerated Approval (United States), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC26H33FN4O7

InChIKeyLBWFXVZLPYTWQI-IPOVEDGCSA-N

CAS Registry341031-54-7

528

Clinical Trials associated with Sunitinib Malate

CTIS2025-523903-31-00

/ Not yet recruitingPhase 3IIT

Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.

Start Date30 Sep 2026

Sponsor / Collaborator

Fondazione Irccs Istituto Nazionale Dei Tumori

NCT07667751

/ RecruitingPhase 2IIT

An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer

The R0 resection rate in neoadjuvant chemotherapy for advanced ovarian cancer remains below 50%, indicating unmet clinical needs. Tyrosine kinase inhibitors (TKIs) can induce immune microenvironment remodeling and exhibit synergistic effects with immune checkpoint inhibitors. To further evaluate the efficacy and safety of epalolide combined with torvolumab plus sunitinib and olaparib as neoadjuvant therapy in HRD-positive untreated patients with advanced ovarian cancer, a prospective, multicenter, single-arm exploratory study is proposed. This study will enroll 35 untreated HRD-positive advanced ovarian cancer patients who will receive neoadjuvant treatment with epalolide plus torvolumab combined with sunitinib and olaparib. Patients achieving CR/PR/SD after neoadjuvant therapy will undergo intermediate tumor cytoreductive surgery, followed by 6 cycles of adjuvant chemotherapy and 1 year of maintenance therapy with the etoricoxib-drug combination antibody regimen. The primary endpoint is R0 resection rate, aiming to provide valuable insights into neoadjuvant treatment strategies for advanced ovarian cancer patients.

Start Date01 Jun 2026

Sponsor / Collaborator

Anhui Provincial Cancer Hospital

[+1]

NCT07477457

/ RecruitingPhase 2IIT

OstEvo - Osteosarcoma Evolves

The researchers are doing this study to find out whether adding gefitinib, trametinib, disulfiram, and sunitinib to standard chemotherapy is a more effective treatment approach for people with osteosarcoma than standard chemotherapy on its own. The researchers will also look at the safety of adding these drugs to standard chemotherapy. The researchers will also use the additional research biopsies from Cohort 1 participants to learn more about how osteosarcoma survives during chemotherapy.

Start Date11 Mar 2026

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

100 Clinical Results associated with Sunitinib Malate

100 Translational Medicine associated with Sunitinib Malate

100 Patents (Medical) associated with Sunitinib Malate

8,163

Literatures (Medical) associated with Sunitinib Malate

01 Jan 2027·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Super-resolution imaging with a mitochondria-targeted fluorescent probe: Evaluation of chemotherapy-induced hepatorenal injury

Article

Author: Liu, Qicheng ; Zhu, Haiying ; Yang, Lei ; Hu, Lin ; Peng, Weikang ; You, Runchuan ; Zhao, Yanjun ; He, Long

With the rising global incidence of cancer, anticancer drugs including cisplatin (DDP) and sunitinib (SU) are being widely used in clinical practice. However, severe nephrotoxicity of DDP and prominent hepatotoxicity of SU drastically restrict their clinical application. Therefore, real-time monitoring of liver and kidney function, along with early intervention of tissue damage progression, is essential during treatment. To address this challenge, we have herein developed a mitochondria-targeted super-resolution fluorescent probe ARP for hypochlorous acid (HClO). ARP's dual recognition sites and dual-signal detection ability significantly enhance its detection accuracy. Combined with super-resolution imaging technology, ARP elucidates the mechanism of ROS transformation induced by DDP and SU at the subcellular level. In vivo assays further validate the tissue-damage mechanisms of these two drugs and evaluate the protective effect of N-acetylcysteine (NAC) on the kidney and of silybin on the liver against drug-induced injury. The results demonstrate that both protective agents effectively alleviate hepatokidney damage without compromising the anti-tumor efficacy of the chemotherapeutic drugs. Hence, this work elucidates the anti-tumor and tissue injury mechanisms of DDP and SU in complex biological systems, providing a new strategy for mitigating drug-induced organ toxicity and offering a solid experimental basis for the rational design of clinical tumor chemotherapy regimens.

31 Dec 2026·Human Vaccines & Immunotherapeutics

Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States

Article

Author: Yan, Chunyan ; Zhao, Quan ; Li, Jiayan ; Diao, Ruigang ; Gao, Yuan ; Li, Zhengxiong

Immunotherapy‑based combination regimens provide significant clinical benefits but impose substantial economic burdens on national healthcare systems. This study assessed the cost-effectiveness of immunotherapy‑based combination regimens as first-line treatments for advanced renal cell carcinoma (aRCC) in China and the United States (US). A partitioned survival model was developed to evaluate the cost-effectiveness of all approved regimens with a lifetime horizon. The primary outcomes were total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). Sensitivity analyses were performed to evaluate model uncertainty. Compared to the sunitinib regimen, the ICERs for the toripalimab plus axitinib (T + A), nivolumab plus ipilimumab (N + I), lenvatinib plus pembrolizumab (L + P), pembrolizumab plus axitinib (P + A), nivolumab plus cabozantinib (N + C), avelumab plus axitinib (A + A) and atezolizumab plus bevacizumab (A + B) regimens in China were $64,536.98/QALY, $135,593.25/QALY, $174,956.58/QALY, $231,908.95/QALY, $728,876.75/QALY, $1,232,070.43/QALY, and $2,496,799.42/QALY, respectively. The ICERs for the N + I, T + A, N + C, P + A, L + P, A + A, and A + B regimens in the US were $160,243.50/QALY, $468,156.65/QALY, $804,963.69/QALY, $907,549.79/QALY, $2,170,769.66/QALY, $2,623,809.39/QALY, and $12,712,147.95/QALY, respectively. Probabilistic sensitivity analyses indicated that the probability of cost-effectiveness corresponding to N + I vs. sunitinib was 33.6% in the US. In China and the US, none of the seven first-line immunotherapy-based combination regimens was cost-effective compared with sunitinib for aRCC.

31 Dec 2026·Future Science OA

A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implications

Article

Author: Andrews, Michael B. ; Thompson, Cameron M. ; Adler, Douglas G.

BACKGROUND:

Treatments for metastatic, unresectable, or treatment-resistant gastrointestinal stromal tumors (GIST) include avapritinib, imatinib, regorafenib, ripretinib, and sunitinib. The FDA Adverse Event Reporting System (FAERS) database collects medication-related adverse events (AEs).

DESIGN AND METHODS:

Reports in the FAERS database from each medication's FDA approval to June 30, 2025 were analyzed. Reports containing other medications or indications outside of GIST treatment were excluded.

RESULTS:

Avapritinib was associated with fatigue (n = 826, 10.2%), nausea/vomiting (n = 574, 7.1%), eye/facial swelling (n = 631, 7.8%), diarrhea n = 361, 4.5%), peripheral edema (n = 231, 2.5%). Imatinib was associated with nausea/vomiting (n = 677, 4.4%), fatigue (n = 549, 3.6%), anemia (n = 404, 2.6%), abdominal pain (n = 400, 2.6%), and rash (n = 340, 2.2%), hemorrhage (317 AEs, 2.1%). Regorafenib was associated with fatigue (n = 104, 8.6%), palmar-plantar erythrodyesthesia syndrome (n = 66, 5.4%), diarrhea (n = 60, 4.9%). Ripretinib was associated with fatigue (n = 534, 8.4%), alopecia (n = 355, 5.6%), nausea/vomiting (n = 273, 4.3%). Sunitinib was associated with fatigue (n = 420, 6.1%%), nausea/vomiting (n = 284, 4.2%), diarrhea (n = 262, 3.8 %), hemorrhage (n = 149, 2.2%).

CONCLUSIONS:

The FAERS database revealed multiorgan AEs associated with five GIST treatment medications. Novel findings include eye/facial and peripheral edema with avapritinib, palmar-plantar erythrodyesthesia syndrome, headache/migraine, and gait abnormalities across all five medications, pancytopenia with imatinib, and hemorrhage with imatinib and sunitinib.

322

News (Medical) associated with Sunitinib Malate

12 Oct 2026

·www.biospace.com

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs

The study met the primary endpoint with a statistically significant and clinically meaningful improvement in progression free survival (PFS) PRINCETON, N.J.--(BUSINESS WIRE)-- $BMY #ACTION -- Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc. , a Bristol Myers Squibb company. The study met the primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival by blinded independent central review, and safety results consistent with the known RYZ101 safety profile. ACTION-1 is a randomized Phase 3 clinical trial evaluating RYZ101 ( 225 Ac-DOTATATE) versus investigator's choice of standard of care (high-dose or high-frequency long-acting somatostatin analogues, everolimus, or sunitinib) in patients with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who have progressed following Lutetium-177 (Lu177)-based therapy. "The improvement in progression-free survival is a defining moment for RYZ101 and for the patients we built this program around — people with advanced GEP-NETs whose cancer has progressed after Lu177-based therapy and who have few remaining options," said Amreen Husain, MD , chief medical officer of RayzeBio. "This is the kind of impact we set out to deliver with actinium-based radiopharmaceuticals, and it is an important milestone supporting the pipeline we are building across our RPT platform. These are the first results from a Phase 3 trial of an alpha-isotope based targeted RPT ( 225 Ac) in any indication, and we are moving with urgency to bring these data to the FDA and, ultimately, provide a novel option for patients." The FDA granted RYZ101 Orphan Drug Designation for the treatment of GEP-NETs in August 2026 based on the significant unmet need facing patients with this disease. That designation, combined with the results of this interim analysis, supports RayzeBio's continued development efforts and plans to engage with the FDA to discuss next steps toward a regulatory submission. Detailed results are expected to be presented at a future medical meeting. “Lu177-based therapy is widely used in GEP-NETs, but unfortunately the vast majority of patients will eventually progress. Determining the optimal treatment after Lu177 has been an important question for my patients, and until now there has been no randomized Phase 3 evidence to guide it,” said Simron Singh, MD, medical oncologist in the Odette Cancer Centre, Sunnybrook Health Sciences Centre, Professor of Medicine at the University of Toronto, and principal investigator of the ACTION-1 study. “ACTION-1 provides the first Phase 3 results for an alpha-based targeted RPT, and a clinically meaningful improvement in progression-free survival is a crucial development in improving the care of patients with GEP-NETs.” Individuals currently enrolled will continue to receive care consistent with the study protocol, and participants will be followed for overall survival. About Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) GEP-NETs are rare tumors, with an estimated incidence of approximately 18,000 patients diagnosed annually in the United States and a prevalence of fewer than 200,000 patients. Somatostatin receptor type 2 (SSTR2) is expressed in 80–90% of GEP-NET tumors, and metastatic disease is present at diagnosis in the vast majority of cases. Lu177-based radiopharmaceutical therapy has shown significant clinical benefit and is approved for adult patients with SSTR-positive GEP-NETs, but most patients invariably progress following treatment, with few effective treatment options available. About RYZ101 RYZ101 is an investigational, targeted radiopharmaceutical therapy comprised of DOTATATE bound to Actinium-225 ( 225 Ac), a highly potent alpha-emitting radioisotope. 225 Ac emits a high-energy, short-range alpha particle that can cause double-stranded DNA damage in cancer cells, potentially resulting in higher chance of cancer cell death. In a Phase 1b trial of 17 previously Lu177-treated patients with disease progression, RYZ101 was well tolerated, with no treatment-related serious adverse events or dose discontinuations due to any adverse event. RYZ101 is also being evaluated in earlier-stage trials in hormone receptor-positive (HR+) metastatic breast cancer. About RayzeBio RayzeBio, Inc., a Bristol Myers Squibb company, develops precision radiopharmaceuticals designed to open new pathways for patients living with cancer. Since its founding in 2020, RayzeBio has built a broad, highly differentiated pipeline supported by capabilities spanning discovery, development, isotope production, and manufacturing across its sites. The company's lead program, RYZ101, is in Phase 3 development for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), alongside programs targeting GPC3, ACP3, next-generation SSTR2-directed therapies, and a number of undisclosed targets. Together, these programs reflect RayzeBio’s ambition to advance the next generation of radiopharmaceutical therapy in service of unmet need for patients. Headquartered in San Diego, California, RayzeBio pairs a nimble, innovative culture with the scale and resources of Bristol Myers Squibb. For more information, visit rayzebio.com . About Bristol Myers Squibb: Transforming Patients’ Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn , X , YouTube , Facebook and Instagram . Cautionary Statement Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that future study results may not be consistent with the results to date, and that RYZ101 ( 225 Ac-DOTATATE) may not receive regulatory approval for the indication described in this release in the currently anticipated timeline or at all, any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether RYZ101 for such indication will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. corporatefinancial-news Contacts Bristol Myers Squibb Media Inquiries: media@bms.com Investors: investor.relations@bms.com

Clinical ResultPhase 3Phase 1Orphan Drug

21 Sep 2026

·www.prnewswire.com

Grünenthal acquires cancer treatment Stivarga®

Latest step in Grünenthal's strategy to acquire established medicines that serve clear medical needs, leverage its commercial and operational capabilities, and drive growth. Stivarga® (regorafenib) is an established oral treatment for certain advanced cancers, including metastatic colorectal cancer, gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma (liver cancer). It is approved and available in more than 90 markets worldwide. Grünenthal has invested around €2.6 billion in successful M&A transactions since 2017, significantly strengthening its profitability and further funding its innovative research pipeline. AACHEN, Germany, Sept. 21, 2026 /PRNewswire/ -- Grünenthal, a global leader in pain management and research, today announced an agreement with Bayer AG to acquire Stivarga®, an oral treatment for specific advanced cancers, for up to €375 million. The acquisition is subject to customary closing conditions, including approval by the relevant regulatory authorities. The acquisition is expected to close by the end of 2026 or early 2027. Stivarga® (regorafenib) is an oral multkinase inhibitor indicated for metastatic colorectal cancer, hepatocellular carcinoma and gastrointestinal stromal tumours (GIST) in patients who have already been treated with, or who cannot be given, other available treatments. It is approved and available in more than 90 markets worldwide. "This acquisition is a strong strategic fit for Grünenthal and reflects our disciplined M&A strategy of acquiring established medicines that address clear and ongoing medical needs and create long-term value," said Gabriel Baertschi, CEO, Grünenthal. "Stivarga® has a well-established role in patient care and the transaction is immediately accretive to our business. By leveraging the strength of our commercial and operational expertise, we see clear opportunities to maximise the value of the medicine and support Grünenthal's long-term growth." Loss of exclusivity for Stivarga® is anticipated in 2029 in the European Union and in 2030 in the United States (US). Grünenthal estimates that Stivarga® may contribute a positive impact on its consolidated EBITDA of up to approximately €100 million for the year ending 31 December 2027, based on an analysis of the information made available to Grünenthal from Bayer and assuming closing by the end of 2026 or the beginning of 2027, as well as a full-year consolidation. The acquisition is the latest development in Grünenthal's M&A strategy and follows the successful integration of several important medicines across a range of health conditions, including the global rights to Nebido™, the rights to Cialis® in Mexico, Brazil and Colombia, the European rights to Crestor™ and Nexium™, and the global rights to Vimovo™ (ex-US and Japan), Zomig™ (ex-Japan) and Qutenza™. In addition to asset acquisitions, earlier this year, Grünenthal acquired full ownership of Grünenthal Meds, a previously joint venture with Kyowa Kirin International to market its established medicines portfolio, and, in 2024, acquired the US company Valinor Pharma and the product Movantik®. The company has invested around €2.6 billion in successful M&A transactions since 2017. About Stivarga ® Stivarga® is a once-daily, oral prescription medicine for certain advanced cancers. It has treated more than one million patients across more than 90 countries over 10 years. In the EU, Stivarga® is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy, as well as for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib, and for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. In the US, Stivarga® is indicated for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy, as well as locally advanced, unresectable or metastatic GIST who have been previously treated with imatinib mesylate and sunitinib malate, and for HCC who have been previously treated with sorafenib. About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2025, Grünenthal employed around 4,100 people and achieved revenues of €1.8 billion. More information: Follow us on LinkedIn & Instagram Advisors Freshfields served as legal counsel to Grünenthal. For further information, please contact: Matt Crabb, Head of Global Communications (Interim), Grünenthal [email protected] SOURCE Grünenthal Group 21% more press release views with Request a Demo

AcquisitionDrug Approval

17 Sep 2026

·www.globenewswire.com

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set for June 29, 2027 Sept. 15, 2026 --- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bezuclastinib in patients with Advanced Systemic Mastocytosis (AdvSM) and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2027. In addition, the FDA communicated that at this time, there is no plan to hold an advisory committee, nor have they identified any potential review issues. “With the FDA’s acceptance of our NDA in Advanced Systemic Mastocytosis, we have reached another important regulatory milestone for bezuclastinib and are one step closer to potentially bringing this therapy to patients with AdvSM,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “Together with the NDAs currently under review for NonAdvSM and GIST patients, this milestone further reinforces the potential of bezuclastinib across multiple patient populations with KIT-driven diseases. With an excellent commercial and medical team in place, we are excited and ready for the potential launches later this year.” The NDA acceptance is supported by data from the APEX pivotal trial, which was most recently presented at the 2026 European Hematology Association (EHA) Congress, in which bezuclastinib demonstrated clinically meaningful responses and durable clinical activity in patients with AdvSM. As of the March 31, 2026 data cutoff, the primary endpoint of response per mIWG-MRT-ECNM criteria demonstrated a 65% overall response rate, including 57% of patients achieving CR, CRh or PR as best response. Response by pure pathological response (PPR) criteria was 81%. Bezuclastinib also demonstrated durable clinical activity, with a 12-month progression-free survival rate of 79% and 12-month overall survival rate of 87%, with median PFS and OS not yet mature. Cogent continues to advance bezuclastinib toward potential approvals and commercialization across its three indications. The Company’s NDA for NonAdvanced Systemic Mastocytosis is under FDA review, with a PDUFA target action date of December 30, 2026, and the NDA for GIST is also under FDA review, with a PDUFA target action date of November 30, 2026. Together, these regulatory milestones represent significant progress toward bringing bezuclastinib to patients across a broad spectrum of KIT-driven diseases. Working with the FDA, Cogent has established active Expanded Access Programs (EAPs) for U.S. patients with SM or GIST who meet disease-specific criteria and could benefit from treatment with bezuclastinib or the combination of bezuclastinib and sunitinib. Cogent also announced today that, on September 10, 2026, the Compensation Committee of Cogent’s Board of Directors, made up entirely of independent directors, approved the grants of “inducement” equity awards to nine new employees under the company’s 2020 Inducement Plan with grant dates of September 10, 2026 and September 14, 2026. The awards were approved in accordance with Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market. The employees received, in the aggregate, (i) nonqualified options to purchase 39,300 shares of Cogent common stock and (ii) 33,600 restricted stock units (RSUs). Each option has a 10-year term, an exercise price equal to the closing price of Cogent’s common stock on the grant date, and a 4-year vesting schedule with 25% vesting on the 1-year anniversary of the grant date and the remainder vesting in equal monthly installments over the subsequent 36 months, provided such employee remains employed through each such vesting date. The RSUs vest annually in equal installments over 4 years from the grant date, provided such employee remains employed through each such vesting date. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. The content above comes from the network. if any infringement, please contact us to modify.

NDAClinical Result

100 Deals associated with Sunitinib Malate

External Link

KEGG	Wiki	ATC	Drug Bank
D06402	Sunitinib Malate	L01EX01	DB01268

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Malignant Gastric Gastrointestinal Stromal Tumor	European Union	Accord Healthcare SL	11 Feb 2021
Malignant Gastric Gastrointestinal Stromal Tumor	Iceland	Accord Healthcare SL	11 Feb 2021
Malignant Gastric Gastrointestinal Stromal Tumor	Liechtenstein	Accord Healthcare SL	11 Feb 2021
Malignant Gastric Gastrointestinal Stromal Tumor	Norway	Accord Healthcare SL	11 Feb 2021
Islet Cell Carcinoma	United States	C.P. Pharmaceuticals International CV	20 May 2011
Islet Cell Adenoma	China	Pfizer Inc.	30 Oct 2007
Metastatic Renal Cell Carcinoma	European Union	Pfizer Ltd.	19 Jul 2006
Metastatic Renal Cell Carcinoma	Iceland	Pfizer Ltd.	19 Jul 2006
Metastatic Renal Cell Carcinoma	Liechtenstein	Pfizer Ltd.	19 Jul 2006
Metastatic Renal Cell Carcinoma	Norway	Pfizer Ltd.	19 Jul 2006
Neuroendocrine tumor of pancreas	European Union	Pfizer Ltd.	19 Jul 2006
Neuroendocrine tumor of pancreas	Iceland	Pfizer Ltd.	19 Jul 2006
Neuroendocrine tumor of pancreas	Liechtenstein	Pfizer Ltd.	19 Jul 2006
Neuroendocrine tumor of pancreas	Norway	Pfizer Ltd.	19 Jul 2006
Pancreatic neuroendocrine tumour metastatic	European Union	Pfizer Ltd.	19 Jul 2006
Pancreatic neuroendocrine tumour metastatic	Iceland	Pfizer Ltd.	19 Jul 2006
Pancreatic neuroendocrine tumour metastatic	Liechtenstein	Pfizer Ltd.	19 Jul 2006
Pancreatic neuroendocrine tumour metastatic	Norway	Pfizer Ltd.	19 Jul 2006
Renal Cell Carcinoma	United Kingdom	Pfizer Ltd.	19 Jul 2006
Well Differentiated Pancreatic Endocrine Tumor	European Union	Pfizer Ltd.	19 Jul 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Renal Cell Carcinoma	Phase 3	United States	MSD KK (Tokyo)	01 Oct 2016
Locally Advanced Renal Cell Carcinoma	Phase 3	Japan	MSD KK (Tokyo)	01 Oct 2016
Locally Advanced Renal Cell Carcinoma	Phase 3	Brazil	MSD KK (Tokyo)	01 Oct 2016
Locally Advanced Renal Cell Carcinoma	Phase 3	Canada	MSD KK (Tokyo)	01 Oct 2016
Locally Advanced Renal Cell Carcinoma	Phase 3	Czechia	MSD KK (Tokyo)	01 Oct 2016
Locally Advanced Renal Cell Carcinoma	Phase 3	France	MSD KK (Tokyo)	01 Oct 2016
Locally Advanced Renal Cell Carcinoma	Phase 3	Germany	MSD KK (Tokyo)	01 Oct 2016
Locally Advanced Renal Cell Carcinoma	Phase 3	Hungary	MSD KK (Tokyo)	01 Oct 2016
Locally Advanced Renal Cell Carcinoma	Phase 3	Ireland	MSD KK (Tokyo)	01 Oct 2016
Locally Advanced Renal Cell Carcinoma	Phase 3	Italy	MSD KK (Tokyo)	01 Oct 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02693535 (TAPUR, Pubmed \| JCO Precis Oncol)	Phase 2	FGFR1 positive Solid Tumors FGFR1 \| FGFR2	64	Sunitinib (FGFR1)	uqjjfwipwz(bhdhwnegxu) = khstezoyop awykjnjjpd (yiassftflr, 12 - 100) View more	Positive	01 Oct 2026
				Sunitinib (FGFR2)	uqjjfwipwz(bhdhwnegxu) = rctwdzeejf awykjnjjpd (yiassftflr, 27 - 100) View more
CSCO2026	Not Applicable	Esophageal Perforation \| Ulcer of esophagus	8,061	Doxycycline	jgnrhlnnya(qrrgckgdkb) = asjesmcmyt caxmstwzhx (cmgprjhrxc ) View more	Positive	11 Sep 2026
				Alendronic acid	jgnrhlnnya(qrrgckgdkb) = qrvwjycdpb caxmstwzhx (cmgprjhrxc )
NCT00715442 (ASCO2026)	Phase 2	Metastatic Renal Cell Carcinoma	46	Sunitinib	nmoybgyzac(kwbcbaslns) = rytmamsvbe xubpzgiqjp (boevdlqutd, 6.1 - 19.3) View more	Positive	29 May 2026
AUA2026	Phase 3	Metastatic Renal Cell Carcinoma First line	4	Nivolumab-cabozantinib	yqunjvxxbm(jepnaybtde) = iadsytexhb apaqicntqt (xbmsxbdhra ) View more	Positive	15 May 2026
				Lenvatinib-pembrolizumab	yqunjvxxbm(jepnaybtde) = gjlzpuqaei apaqicntqt (xbmsxbdhra ) View more
ESMO_SRC2026	Not Applicable	SDH-deficient Gastrointestinal Stromal Tumors	19	imatinib	efokbxjaln(lqhmddqpcy) = mrtryfufrv azgheuszae (cyibwzjpcd, 50.7 - NR)	Positive	09 Mar 2026
				sunitinib	ugsfgfunwd(imtqsommls) = ltwdfduesx xjqjgfyfhw (luiyeselcy )
ESMO_ASIA2025	Not Applicable	Pheochromocytoma	46	sunitinib	usptazrdzr(nfsfxvmzfz) = kjlrqbuhcc fulyradlte (izommnexkl, 6.4 - 18.7) View more	Positive	05 Dec 2025
				alkylating agents-based chemotherapy (ChT)	usptazrdzr(nfsfxvmzfz) = vbpcxvdnvl fulyradlte (izommnexkl, 8.3 - 17.1) View more
NCT05208047 (PEAK, Company_Website) Manual	Phase 3	Gastrointestinal Stromal Tumors Second line	-	bezuclastinib + sunitinib	dtpnzetvxr(ojlxyqqadm) = zmjdfiwddh jisngvqrji (qentlrxshl ) View more	Positive	10 Nov 2025
				sunitinib	dtpnzetvxr(ojlxyqqadm) = gjmjuzgoli jisngvqrji (qentlrxshl ) View more
NCT03277924 (IMMUNOSARC II, ESMO2025)	Phase 2	Alveolar Soft Part Sarcoma First line	18	Sunitinib plus nivolumab	ltztcmrebt(oyzkaefutd) = jrkeoplxbe ndxqvlkxoj (ngjvazozlq, 19 - 77) View more	Positive	17 Oct 2025
				Sunitinib plus nivolumab (treatment naïve)	ltztcmrebt(oyzkaefutd) = ftzztgsfpf ndxqvlkxoj (ngjvazozlq, 19 - 77) View more
NCT02684006 (JAVELIN Renal 101, ESMO2025)	Phase 2/3	Metastatic Renal Cell Carcinoma sMAdCAM-1	1,051	Avelumab + Axitinib	muhxrcuvrw(ohmktigehd): HR = 0.59 (95.0% CI, 0.41 - 0.85), P-Value = 0.004 View more	Positive	17 Oct 2025
				Sunitinib
NCT02684006 (JAVELIN Renal 101, ESMO2025)	Phase 3	Renal Cell Carcinoma \| Non-Small Cell Lung Cancer	824	Atezolizumab	jqkvuwwnoc(rxnkqwvmlm) = honapqegff uubxakgyeu (zfrmsjlasq, 22 - 33)	Positive	17 Oct 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis